This clinical trial is focused on studying a condition called neovascular age-related macular degeneration (nAMD), which affects the eyes and can lead to vision loss. The study is testing a new treatment called RGX-314, which is a type of gene therapy. Gene therapy involves using genes to treat or prevent diseases. In this case, RGX-314 is designed to help manage nAMD by targeting a specific protein involved in the disease process. The study will compare the effectiveness and safety of RGX-314 with another treatment called aflibercept, which is already used to treat nAMD. Aflibercept is given as an injection into the eye to help reduce vision loss.

The purpose of the study is to see if RGX-314 is not worse than aflibercept in improving vision over a period of time. Participants in the study will receive either RGX-314 or aflibercept, and some may receive a placebo. The study will last for about 54 weeks, during which participants will have regular check-ups to monitor their vision and overall health. The study aims to find out if RGX-314 can help maintain or improve vision in people with nAMD, and if it can reduce the need for additional treatments.

Throughout the study, participants will undergo various assessments to track changes in their vision and any side effects they might experience. The study will also look at how often participants need additional treatments to manage their condition. By the end of the study, researchers hope to gather enough information to determine if RGX-314 is a safe and effective treatment option for people with neovascular age-related macular degeneration.